EXPLORE THE SCIENCE
TL;DR: A 2026 preprint in medRxiv warned that a standard Alzheimer’s disease biomarker-clock analysis can create a countdown paradox, where later biomarker-clock ages appear linked to faster mild cognitive impairment onset because of the way remaining time is…
Read article
TL;DR: A 2026 real-world cohort study in The Journal of Prevention of Alzheimer’s Disease found that lecanemab-treated Alzheimer’s patients had lower Neuropsychiatric Inventory scores over follow-up, and 6-month symptom reductions were associated with regional…
Read article
TL;DR: A 2026 ADNI analysis posted to medRxiv found that brain-derived plasma pTau217 better predicted near-term amyloid positron emission tomography (PET) positivity than total plasma pTau217 in cognitively unimpaired amyloid-negative participants. Key Findin…
Read article
TL;DR: A 2026 narrative review in the Japanese Journal of Radiology reported that Alzheimer’s brain positron emission tomography (PET) imaging has shifted from supportive diagnosis toward treatment selection because amyloid PET is now central to confirming eli…
Read article
TL;DR: A 2026 medRxiv preprint found that plasma p-tau217 AI models still separated amyloid-positive from amyloid-negative people across ADNI and A4, but calibration drift made the same probabilities less dependable for clinical decisions. Key Findings Calibra…
Read article
TL;DR: A 2026 systematic review and meta-analysis in Molecular Neurobiology found that plasma phosphorylated tau 217 (p-tau217), a blood marker of Alzheimer-linked tau pathology, identified biomarker-defined Alzheimer’s disease with pooled sensitivity of 85.4%…
Read article